Safety, Tolerability, and Pharmacokinetics of Telacebec (Q203), a New Antituberculosis Agent, in Healthy Subjects
Jeongjun Kim, Jin‐Ho Choi, Hwankyu Kang, Jiye Ahn, Jane Hutchings, Christo van Niekerk, Dongsik Park, Jaeseung Kim, Yeejin Jeon, Kiyean Nam, Soyoung Shin, Beom Soo Shin
Abstract
Telacebec (Q203) is a potent drug candidate under clinical development for the treatment of drug-naïve and drug-resistant tuberculosis. The first-in-human randomized, placebo-controlled, double-blind, dose-escalation Phase 1A trial (Q203-TB-PI-US001) was conducted to evaluate the safety, tolerability, and pharmacokinetics of telacebec.
Topics & Concepts
TolerabilityPharmacokineticsPharmacologyMedicineAdverse effectTuberculosis Research and EpidemiologyMycobacterium research and diagnosisCancer therapeutics and mechanisms